Atopic Dermatitis

In this Q&A, Armand explains why eczema visits spike during wildfire smoke events and how allergic patients can protect themselves.

In this feature, several leaders in the dermatology space were asked how far we have come and where the field is headed in precision medicine.

New research links wildfire smoke to lasting respiratory decline and skin flares, months after exposure ends.

Peter Lio, MD, breaks down AdvanceAD-Tx testing and oral STAT6 degrader KT-621 in the atopic dermatitis pipeline.

The oral STAT6 degrader achieved deep STAT6 suppression, up to 63% EASI reduction, and gains in asthma and rhinitis scores by week 4.

Dallas allergist-immunologists discuss real-world use of non-steroidal topicals in AD, steroid phobia, and the nematode story.

In this discussion, Eichenfield discusses which advances in eczema he sees as most impactful and where unmet needs remain for pediatric patients.

This Q&A highlights recent data and FDA approvals described in the pediatric atopic dermatitis space by Lawrence Eichenfield, MD.

Lawrence Eichenfield, MD, breaks down new AAD pediatric atopic dermatitis guidelines, covering prevention strategies and linked comorbidities.

Linda Stein Gold, MD, discusses age-stratified ADORING data on tapinarof cream for atopic dermatitis, presented at the 2026 SPD Annual Meeting.

Linda Stein Gold, MD, discusses ADORING trial endpoints and remaining treatment gaps in the youngest patients with atopic dermatitis.

Linda Stein Gold, MD, explains what new ADORING data reveal about tapinarof cream for atopic dermatitis across age cohorts.

New phase 3 data show tapinarof cream (VTAMA) delivered early, consistent efficacy across pediatric and adult age groups with atopic dermatitis.

Lebrikizumab improved itch, quality of life, and infection rates in kids with moderate-to-severe atopic dermatitis, ADorable-1 results suggest.

New phase 3 ADorable-1 data show lebrikizumab improved skin clearance in children with moderate-to-severe atopic dermatitis.

NYC allergists discuss tapinarof's 80-day treatment-free interval, ruxolitinib's box warning hurdles, and more.

Moderator Greg Bensch and a panel of allergists discuss itch control, access barriers, and guideline gaps shaping newer AD topicals in this clinical forum.

How should clinicians choose atopic dermatitis treatments? Harrison Nguyen, MD, discusses personalized therapy and when to escalate care.

How is drug selection evolving in atopic dermatitis? Walter Liszewski, MD, discusses personalized therapy and long-term care.

Organon reports pooled phase 3 data showing tapinarof cream (VTAMA) improved atopic dermatitis severity across pediatric and adult age groups by Week 8.

Walter Liszewski, MD, discusses how dermatologists can personalize atopic dermatitis treatment using biologics, JAK inhibitors, and topicals.

Sanofi has discontinued development of OX40L-targeting amlitelimab for atopic dermatitis, following the heels of Kyowa Kirin's similar rocatinlimab discontinuation.

Jason Hawkes, MD, explains how new biologics and targeted therapies are advancing precision medicine and improving personalized care in atopic dermatitis.

Jason Hawkes, MD, highlights issues related to prior authorization as well as raising awareness of chronic urticaria, HS, atopic dermatitis, and other diseases.

Experts unpack where new eczema creams fit, and why insurance hurdles and steroid fear keep patients from faster itch relief.